Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis

Published:2016-10-24 Issue:11-12 Volume:44 Page:1183-1198
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Harrison S. A.¹,Marri S. R.²,Chalasani N.²,Kohli R.³,Aronstein W.³,Thompson G. A.⁴,Irish W.³,Miles M. V.³,Xanthakos S. A.³,Lawitz E.⁵,Noureddin M.⁶,Schiano T. D.⁷,Siddiqui M.⁸,Sanyal A.⁹,Neuschwander-Tetri B. A.⁹,Traber P. G.¹⁰¹¹

Affiliation:

1. Fort Sam Houston TX USA

2. Indianapolis IN USA

3. Cincinnati OH USA

4. West Chester OH USA

5. San Antonio TX USA

6. Los Angeles CA USA

7. New York NY USA

8. Richmond VA USA

9. St. Louis MO USA

10. Norcross GA USA

11. Atlanta GA USA

Funder

Galectin Therapeutics Inc

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13816/fullpdf

Reference28 articles.

1. When galectins recognize glycans: from biochemistry to physiology and back again;DiLella;Biochemistry,2011

2. Galectin-3 regulates myofibroblast activation and hepatic fibrosis;Henderson;Proc Natl Acad Sci USA,2006

3. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3;MacKinnon;Am J Respir Crit Care Med,2012

4. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis;Henderson;Am J Pathol,2008

5. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver;Iacobini;J Hepatol,2011

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial Dynamics;Livers;2024-09-13

3. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease;Hormones;2024-08-07

4. Potential therapeutic strategies for MASH: from preclinical to clinical development;Life Metabolism;2024-07-06

5. Macrophage Perspectives in Liver Diseases: Programmed Death, Related Biomarkers, and Targeted Therapy;Biomolecules;2024-06-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3